期刊
HEMATOLOGY TRANSFUSION AND CELL THERAPY
卷 43, 期 1, 页码 9-14出版社
ELSEVIER
DOI: 10.1016/j.htct.2019.10.007
关键词
Acute lymphoblastic leukemia; Asparaginase; Hypersensitivity; Children
The study found that IV administration and commercial Leuginase (R) presentation were associated with more allergic reactions in pediatric leukemia patients. The IV route was also associated with higher severity of reactions in this study.
Introduction: To assess the frequency of allergic reactions to asparaginase (ASP) and possible risk factors for reactions in a cohort of pediatric patients. Method: The study was performed based on retrospective data from patients under acute lymphoid leukemia treatment in a general university hospital located in southern Brazil. Information on patients who used ASP from 2010 to 2017 was collected. Allergic reactions were identified in electronic medical records. Results: Among the 98 patients included in the study, 16 (16.3 %) experienced an allergic reaction to native L-asparaginase (L-ASP). Of the 22 patients (22.4 %) that received only intravenous (IV) administration of L-ASP, 10 (62.5 %) had allergic reactions, while 48 patients (49 %) received intramuscular (IM) administration and 28 (28.6 %) received IV and IM administrations. The occurrence of allergic reactions differed between the groups (p < 0.001), and IV administration was associated with allergic reactions. Association was also observed between the severity of the reaction and the route of administration, with the IM route associated with grade 2 and IV route associated with grade 3. Occurrence of allergic reactions was higher when the commercial formulation of L-ASP, Leuginase (R), was used (p = 0.0009 in the analysis per patient and p = 0.0003 in the analysis per administration). Conclusions: The IV administration and commercial Leuginase (R) presentation were associated with more allergic reactions in the study population, which corroborates the findings in the literature. The IV route was also associated with higher severity of reactions in the present study. (C) 2020 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据